Long-term resolution of immunological graft rejection after a dexamethasone intravitreal implant

Paolo Vinciguerra, Elena Albé, Riccardo Vinciguerra, Mario M. Romano, Silvia Trazza, Leonardo Mastropasqua, Daniel Epstein

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To present the results of the injection of an intravitreal implant of dexamethasone 0.7 mg (DEX 0.7 mg) in 4 patients with an immunologic graft rejection after penetrating keratoplasty. Methods: Two of the patients received DEX 0.7 mg because inflammation and corneal edema not related to endothelial cell loss persisted despite the administration of topical prednisolone acetate, subconjunctival betamethasone, and systemic methylprednisolone. The other 2 cases received DEX 0.7 mg at the time rejection was diagnosed. Results: At 1 and 6 months after implantation, all rejection episodes resolved with improvement in uncorrected and bestcorrected visual acuity, restoration of graft transparency, reduction of central corneal thickness, and no significant increase in intraocular pressure. Conclusions: In 4 eyes with an immunologic graft rejection after penetrating keratoplasty, the dexamethasone 0.7 mg intravitreal implant was an effective treatment option, even in cases refractory to standard topical and systemic therapy.

Original languageEnglish
Pages (from-to)471-474
Number of pages4
JournalCornea
Volume34
Issue number4
DOIs
Publication statusPublished - Mar 21 2015

Keywords

  • dexamethasone 0.7 mg
  • immunologic graft rejection
  • keratoconus
  • Ozurdex
  • penetrating keratoplasty

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Long-term resolution of immunological graft rejection after a dexamethasone intravitreal implant'. Together they form a unique fingerprint.

Cite this